Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Trial ID or NCT#
NCT00952380
Status
NOT RECRUITING
Purpose
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Official Title
A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES
Eligibility Criteria
Ages Eligible for Study: Younger than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- -
Exclusion Criteria:
- -
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Peds Hem/Onc CRAs
650-723-5535
View on ClinicalTrials.gov
